Related Experiment Video
Updated: May 6, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Knockdown of EPS8 expression attenuates the proliferation of enzalutamide-resistant prostate cancer cells
Wei-Lun Huang1,2,3, Sih-Han Chen1,2,3,4, Richard Chen-Yu Wu1,2,5
1Division of Urology, Department of Surgery, E-Da Hospital Kaohsiung 824, Taiwan.
Abstract:
Androgen deprivation therapies, the key treatment options for prostate cancer, have shown resistance and disease progression in many patients receiving these treatments. Therefore, it is crucial to identify new targetable pathways. Epidermal growth factor receptor pathway substrate 8 (Eps8) is one such potential target. Although this pathway is associated with the progression of various cancers, studies on the role of Eps8 in prostate cancer remain limited. This study investigated the role of Eps8 in prostate cancer. The LNCaP cell line and enzalutamide-resistant LNCaP (LNCaP Enz-R) cell lines were utilized for the investigation. Overexpression of Eps8 was observed in the LNCaP Enz-R cells. Transfecting pCMV-EPS8 also increased the levels of epithelial-to-mesenchymal transition (EMT), cell proliferation, and cell viability in both cell lines. Conversely, knockdown of Eps8 expression decreased the levels of EMT, cell proliferation, and cell viability in both cell lines. Furthermore, EPS8-induced EMT activation could be reversed by suppressing the Ras/JAK/PI3K signaling pathway. In vivo animal study also confirmed the crucial role of Eps8 expression in prostate cancer progression. Therefore, we suggest that targeting Eps8 by knocking down its expression is promising as a therapeutic approach for prostate cancer treatment.
Insights
Targeting Epidermal growth factor receptor pathway substrate 8 (Eps8) shows promise for prostate cancer treatment. Knocking down Eps8 inhibits cancer progression, offering a potential new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Androgen deprivation therapies are standard for prostate cancer but often face resistance and disease progression.
- New therapeutic targets are needed to overcome treatment resistance in prostate cancer.
- Epidermal growth factor receptor pathway substrate 8 (Eps8) is implicated in various cancers but its role in prostate cancer is underexplored.
Purpose of the Study:
- To investigate the role of Eps8 in prostate cancer progression.
- To evaluate Eps8 as a potential therapeutic target for prostate cancer.
Main Methods:
- Utilized LNCaP and enzalutamide-resistant LNCaP (LNCaP Enz-R) cell lines.
- Overexpressed and knocked down Eps8 expression in prostate cancer cells.
- Assessed epithelial-to-mesenchymal transition (EMT), cell proliferation, and viability.
- Investigated the involvement of the Ras/JAK/PI3K signaling pathway.
- Conducted in vivo animal studies.
Main Results:
- Eps8 was overexpressed in enzalutamide-resistant prostate cancer cells.
- Eps8 overexpression increased EMT, proliferation, and viability.
- Eps8 knockdown decreased EMT, proliferation, and viability.
- EPS8-induced EMT was reversible by inhibiting the Ras/JAK/PI3K pathway.
- In vivo studies confirmed Eps8's role in prostate cancer progression.
Conclusions:
- Eps8 plays a crucial role in prostate cancer progression.
- Targeting Eps8 through knockdown presents a promising therapeutic strategy for prostate cancer.
- Inhibition of Eps8 may overcome resistance to current therapies.
More Related Videos
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
